Alcobra prices upsized IPO at $8, below the range

Comment

Shutterstock photo

Alcobra, an Israeli drug company developing a non-stimulant ADHD treatment, raised $25 million by offering 3.1 million shares at $8. The company had planned to offer 2.3 million shares at $10 to $12; total proceeds were $25 million, as expected. Alcobra plans to list on the NASDAQ under the symbol ADHD. Aegis Capital acted as the sole bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com